Oct12Mon

Member News from Reading Terminal Market

Reading Terminal Market launches $250,000 crowdfunding campaign to offset pandemic losses
Philadelphia Business Journal

Philadelphia’s historic Reading Terminal Market has launched a crowdfunding campaign for the first time in its 128-year history in efforts to offset losses from the Covid-19 pandemic.

Launched via online crowdsourcing platform GoFundMe, the campaign has a goal of $250,000 and will run through the end of 2020. As of early Friday afternoon, just over $11,000 had been raised from 116 people.

The cash will go toward helping the public market stay open seven days a week, maintaining peak HVAC and ventilation operations, and subsidizing the extra cleaning and disinfecting practices in place during the health crisis. The fund will also help one of the city’s most popular attractions continue offering its various events and community programs, such as nutrition programs and food rescue collaborations with other local nonprofits like Philabundance, said General Manager Conor Murphy.

Read More

Oct08Thu

Member News from Emergent Bio

Emergent BioSolutions announced that its COVID-19 Human Immune Globulin (COVID-HIG) product candidate will be evaluated in an NIH-sponsored phase 3 clinical trial of hyperimmune intravenous immunoglobulins to treat COVID-19

GAITHERSBURG, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of the Phase 3 clinical trial that will evaluate plasma-derived therapy COVID-HIG as a potential treatment for hospitalized patients with coronavirus disease (COVID-19). The INSIGHT-013 clinical study called “Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC),” is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study will evaluate the safety, tolerability, and efficacy of hyperimmune globulin products derived from plasma of individuals who have recovered from COVID-19 and have developed neutralizing antibodies to SARS-CoV-2, the virus that causes COVID-19. The randomized controlled clinical trial assigns participants to receive infusions of either a placebo or one of four hyperimmune globulin products, which includes Emergent’s COVID-HIG, with a background therapy of remdesivir in all groups.

Read More

Sep29Tue

Member News from Neumann University

Neumann University Sisters Offer Prayers From the Porch
Delco Today

Coronavirus has caused most of the Sisters of St. Francis at Neumann University to maintain a healthy social distance from the students there.

Despite this hurdle, Sr. Marguerite O’Beirne, OSF, Neumann’s vice president for mission and ministry, and Sr. Linda DeCero, OSF, director of pastoral ministry, aren’t letting the virus interfere with their roles on campus.

Read More